 |
PDBsum entry 2vvu
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Blood clotting
|
PDB id
|
|
|
|
2vvu
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Blood clotting
|
 |
|
Title:
|
 |
Aminopyrrolidine factor xa inhibitor
|
|
Structure:
|
 |
Activated factor xa heavy chain. Chain: a. Fragment: catalytic, residues 235-475. Engineered: yes. Mutation: yes. Factor x light chain. Chain: l. Fragment: egf2, residues 126-180. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
2.30Å
|
R-factor:
|
0.220
|
R-free:
|
0.309
|
|
|
Authors:
|
 |
K.Groebke-Zbinden,D.W.Banner,J.M.Benz,F.Blasco,G.Decoret,J.Himber, B.Kuhn,N.Panday,F.Ricklin,P.Risch,D.Schlatter,M.Stahl,R.Unger,W.Haap
|
|
Key ref:
|
 |
K.G.Zbinden
et al.
(2009).
Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit.
Eur J Med Chem,
44,
2787-2795.
PubMed id:
|
 |
|
Date:
|
 |
|
11-Jun-08
|
Release date:
|
07-Jul-09
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains A, L:
E.C.3.4.21.6
- coagulation factor Xa.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Preferential cleavage: Arg-|-Thr and then Arg-|-Ile bonds in prothrombin to form thrombin.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
Eur J Med Chem
44:2787-2795
(2009)
|
|
PubMed id:
|
|
|
|
|
| |
|
Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit.
|
|
K.G.Zbinden,
L.Anselm,
D.W.Banner,
J.Benz,
F.Blasco,
G.Décoret,
J.Himber,
B.Kuhn,
N.Panday,
F.Ricklin,
P.Risch,
D.Schlatter,
M.Stahl,
S.Thomi,
R.Unger,
W.Haap.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Starting from a hit identified by focused screening, 3-aminopyrrolidine factor
Xa inhibitors were designed. The binding mode as determined by X-ray structural
analysis as well as the pharmacokinetic behaviour of selected compounds is
discussed.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.J.Huang,
J.Wu,
Z.Q.Cai,
and
J.Yuan
(2011).
4-(3-Fluoro-4-nitro-phen-yl)morpholin-3-one.
|
| |
Acta Crystallogr Sect E Struct Rep Online,
67,
o1549.
|
 |
|
|
|
|
 |
C.Bissantz,
B.Kuhn,
and
M.Stahl
(2010).
A medicinal chemist's guide to molecular interactions.
|
| |
J Med Chem,
53,
5061-5084.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |
|